• WSJ

    • <h4>WSJ on Facebook</h4><div style="border: none; padding: 2px 3px;" class="fb-like" data-href="http://www.facebook.com/wsj" data-send="false" data-layout="button_count" data-width="250" data-show-faces="false" data-action="recommend"></div>
    • <h4>WSJ on Twitter</h4><a href="https://twitter.com/wsj" class="twitter-follow-button" data-show-count="true">Follow @wsj</a>
  • WSJ LIVE

    • WSJ Live on Facebook

    • WSJ Live on Twitter

  • MARKETWATCH

    • MarketWatch on Facebook

    • MarketWatch on Twitter

  • BARRON'S

    • Barron's on Facebook

    • Barron's on Twitter

  • Portfolio

    • Portfolio on Facebook

    • Portfolio on Twitter

  • DJX

    • Product X on Facebook

    • Product X on Twitter

    • RT
    • F
    • R&C
    • PE&VC
    • WSJ
    • B
  • MORE

    • WSJ Secure
    • BigCharts
    • DJX
    • Portfolio
    • WSJ Live
    • Financial News
    • Professor Journal
    • Student Journal
    • Virtual Stock Exchange
    • WSJ Classifieds
    • WSJ Classrooms
    • WSJ Radio
    • WSJ Wine
The Wall Street Journal
Menu
  • Home
  • World
  • U.S.
  • Business
  • Tech
  • Markets
  • Market Data
  • Your Money
  • Opinion
  • Life & Culture
  • N.Y.
  • Real Estate
  • Management

Also in WSJ.com:

  • Latest News
  • Today's Paper
  • Most Popular
  • Streams (TBD)
  • Video
  • Blogs

International Editions

  • U.S.
  • Asia
  • Europe
  • América Latina
  • Brasil
  • 中文-简体(China)
  • Deutschland
  • India
  • Indonesia
  • 日本(Japan)
  • 한국(Korea)
  • Türkiye
Market Data
  • Log In
  • Subscribe

Baxter International Inc. BAX (U.S.: NYSE)

View All companies
  • AT CLOSE 4:00 PM ET 09/15/14
  • $74.55 USD
  • -0.15 -0.20%
  • Volume 1,607,458
  • AFTER HOURS 4:24 PM ET 09/15/14
  • $74.55 0.00 0
  • AFTER HOURS Vol 6,820
  • Volume 1,607,458
  • 65 Day Avg Vol 2,106,440
  • 1 Day Range 74.08 - 74.74
  • 52 Week Range 62.80 - 77.31 (10/02/13 - 07/23/14)
  • 1 Day
  • 5 Day
  • 1 Month
  • 3 Month
  • YTD
  • 1 Year
  • 3 Year
  • $
  • %
Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care
  • Compare to
  • Today's Open 74.74
  • Prior Day Close 74.70 (09/12/14)
  • Performance Today
  • BAX -0.20%
  • DJIA 0.26%
  • S&P 500 -0.07%
  • Health Care -0.38%
Company Overview

Latest News Baxter International Inc.(BAX)

    • 9 hours ago
    • Press Release
    FDA Approves Baxter's RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B
    • Press Release
    • 09/12/14
    • Press Release
    FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency
    • Press Release
    • 09/10/14
    • Dow Jones Newswires
    Baxter Spinoff Drug Business to Be Named Baxalta
    • Dow Jones Newswires
    • 09/10/14
    • Press Release
    Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company
    • Press Release
    • 09/09/14
    • Press Release
    Technical Updates, Upcoming Conferences, and Public Offering Pricing - Research Reports on Coach, NorthStar Realty, Banco Bradesco, BNY Mellon and Baxter
    • Press Release
    • 09/01/14
    • Press Release
    Collaboration Results, Litigation Update, Market Activity, Earnings Release, and Clinical Trial Results - Research Reports on Aetna, Allergan, Valeant, Perrigo and Baxter
    • Press Release
    • 08/12/14
    • The Wall Street Journal
    CSL Weighs New Stock Buyback
    • The Wall Street Journal
    • 08/07/14
    • Press Release
    Financial Results, FDA Approvals, Orphan Drug Designations, and Certificates - Research Reports on Idenix, Baxter, Alexion, Alere and Zoetis
    • Press Release
    • 08/07/14
    • Press Release
    Baxter Opens Its First State-of-the-Art Biologics Facility in Asia, Announces Expansion Plans with New Processing Suite
    • Press Release
    • 08/04/14
    • Press Release
    FDA Approves Baxter's FLEXBUMIN 5%, First and Only 5% Human Albumin Solution in a Flexible Container
    • Press Release
    • 07/31/14
    • Press Release
    FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
    • Press Release
    • 07/30/14
    • WSJ Blogs
    Deals of the Day: AstraZeneca Breathes Deep, FTD's Flower Power
    • WSJ Blogs
    • 07/30/14
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 07/30/14
    • MarketWatch.com
    Pfizer to buy Baxter’s vaccines for $635 million
    • MarketWatch.com
    • 07/30/14
    • The Wall Street Journal
    Pfizer To Buy Baxter's Vaccines
    • The Wall Street Journal
    • 07/30/14
    • Press Release
    Baxter Announces Divestiture of Commercial Vaccines Business to Pfizer
    • Press Release
    • 07/22/14
    • Press Release
    Baxter Declares Quarterly Dividend
    • Press Release
    • 07/21/14
    • Press Release
    Dividend Declaration, Earnings Results Schedules, Product Recall and Joint Open Laboratory Agreement - Analyst Notes on Covidien, Baxter, Cooper, Waters and CareFusion
    • Press Release
    • 07/17/14
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 07/17/14
    • Dow Jones Newswires
    Baxter Profit Falls, But Revenue Beats Expectations
    • Dow Jones Newswires
    • 07/17/14
    • Press Release
    Baxter Exceeds Expectations in Second Quarter with Strong Growth across Global Franchises
    • Press Release
    • 07/11/14
    • Press Release
    Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific
    • Press Release
    • 07/10/14
    • Press Release
    Baxter Appoints John Orloff, M.D., Vice President of BioScience R&D
    • Press Release
    • 07/09/14
    • Press Release
    Baxter Acquires AesRx, LLC, Including Its Investigational Sickle Cell Disease Treatment
    • Press Release
    • 07/08/14
    • Press Release
    Market Activity and Upcoming Quarterly Results - Analyst Notes on Bristol-Myers Squibb, Abbott, Alexion, Mallinckrodt and Baxter
    • Press Release
    • 07/07/14
    • WSJ Blogs
    CFO Moves: Baxter International, Hill-Rom, AngloGold Ashanti
    • WSJ Blogs
    • 07/07/14
    • Press Release
    Baxter Names Chief Financial Officers for New Biopharmaceutical Spin-off and Baxter International Inc.
    • Press Release
    • 06/27/14
    • Press Release
    Product Recalls, Special Tips, Recognitions, New Medical Office, and Collaborations - Analyst Notes on Baxter, WellPoint, HCA, Cigna and Aetna
    • Press Release
    • 06/26/14
    • Press Release
    Baxter International Second Quarter 2014 Financial Results Conference Call
    • Press Release
    • 05/10/14
    • Barron's
    Shareholders Back Buffett on Payout
    • Barron's
    • 05/10/14
    • Barron's
    Shareholders Back Buffett on Payout
    • Barron's
    • 05/07/14
    • MarketWatch.com
    5 quality stocks that are missing out on the bull run
    • MarketWatch.com
    • 04/17/14
    • The Wall Street Journal
    Baxter Profit Edges Up
    • The Wall Street Journal
    • 04/02/14
    • The Wall Street Journal
    Baxter to Acquire Chatham Therapeutics for $70 Million
    • The Wall Street Journal
    • 03/29/14
    • Barron's
    Charting the Market
    • Barron's
    • 03/27/14
    • The Wall Street Journal
    Baxter to Split Into Two Companies
    • The Wall Street Journal
    • 03/27/14
    • WSJ Blogs
    CFO Moves: Merck, Sutron, Oculus
    • WSJ Blogs
    • 03/27/14
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 03/27/14
    • WSJ Blogs
    Stocks to Watch: Citigroup, GameStop, Winnebago
    • WSJ Blogs
    • 03/27/14
    • WSJ Blogs
    Deals of the Day: King Digital's Disastrous Day, Yahoo Japan's Big Deal
    • WSJ Blogs
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    20.82 (09/15/2014)
  • EPS (TTM)
    $3.58
  • Market Cap
    $40.46 B
  • Shares Outstanding
    541.67 M
  • Public Float
    540.46 M
  • Yield
    2.79% (09/15/2014)
  • Latest Dividend
    $0.52 (10/01/2014)
  • Ex-Dividend Date
    09/03/2014
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest

  • Shares Sold Short
    9.12 M (08/29/2014)
  • Change from Last
    -1.63%
  • Percent of Float
    1.69%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    1.28
    Net Money Flow ($)
    +6.42 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors (BAX)

Company Change P/E (TTM)
HSP

Hospira Inc.

+0.30% +0.16 50.76
SYK

Stryker Corp.

-0.07% -0.06 45.82
BDX

Becton Dickinson & Co.

+0.31% +0.35 22.68
ZMH

Zimmer Holdings Inc.

-0.43% -0.45 22.47
BSX

Boston Scientific Corp.

-0.88% -0.11 69.10
BCR

C.R. Bard Inc.

-0.64% -0.95 14.82
TMO

Thermo Fisher Scientific Inc.

-0.76% -0.94 31.20
COV

Covidien PLC

-0.22% -0.20 27.01
STJ

St. Jude Medical Inc.

-1.41% -0.89 19.68
MDT

Medtronic Inc.

-0.37% -0.24 21.72
  • Competitor Data Provided By: capital cube

Profile (BAX)

Baxter International, Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions through its subsidiaries....

One Baxter Parkway
Deerfield Illinois 60015
United States

  • Email
  • Website
  • Map
  • Employees 61,000
    Sector Medical Supplies
  • Sales or Revenue 15.26 B
    Industry Health Care
  • 1Y Sales Change 7.52%
    Fiscal Year Ends December 31 Download Reports
  • Robert L. Parkinson Chairman & Chief Executive Officer
  • Robert J. Hombach Chief Financial Officer & Vice President
  • Paul E. Martin Chief Information Officer & Vice President
  • Ludwig N. Hantson Vice President
  • More

Research & Ratings Baxter International Inc.(BAX)

Per-Share Earnings, Actuals and Estimates

BAX will report FY 2014 earnings on 01/22/2015 BAX will report Q3 earnings on 10/16/2014
  • Quarterly
  • Annual
Actual Analyst Range Consensus
2.00 1.50 1.00 0.50 0.00
Actual 1.19
1.19
Actual 1.32
1.25
Actual 1.19
1.09
Actual 1.26
1.22
1.31
1.40
Q32013 Q4 Q12014 Q2 Q3 Q4
8 5 3 0
Actual 3.66
4.66
5.16
5.31
5.69
FY 2013 FY 2014 FY 2015 FY 2016
Q3 2014 Estimate Trends
Current: $1.31
1 month ago: $1.31
3 months ago: $1.31
Q4 2014 Estimate Trends
Current: $1.40
1 month ago: $1.40
3 months ago: $1.43
FY 2014 Estimate Trends
Current: $5.16
1 month ago: $5.16
3 months ago: $5.15
FY 2015 Estimate Trends
Current: $5.31
1 month ago: $5.37
3 months ago: $5.44
  • More

Financials Baxter International Inc.(BAX)

  • Quarterly
  • Annual

Net Income

0 200M 400M 600M
Jun 2013 Sep 2013 Dec 2013 Mar 2014 Jun 2014
0 600M 1.2B 1.8B 2.4B
'09 '10 '11 '12 '13
Jun 2014 5-quarter trend
Net Income Growth -11.86%
Sales or Revenue 4.26 B
Sales or Revenue Growth +16.13%
EBITDA +989.00 M
2013 5-year trend
Net Income Growth -13.50%
Sales or Revenue 15.26 B
Sales or Revenue Growth +7.52%
EBITDA +4.07 B
  • More

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only. U.S. stock quote data and real-time U.S. stock indexes provided by Dow Jones.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

Bond quotes are updated in real-time. Source: Tullett Prebon PLC, ICAP PLC.

Currency quotes are updated in real-time. Source: ICAP PLC.

Advertisement
  • Wall Street Journal
  • Facebook
  • Twitter
  • LinkedIn
  • FourSquare
  • Google+
  • YouTube
  • Podcasts
  • RSS Feed
  • AppStore
  • Subscribe
  • /Login
  • Back to Top«
  • Customer Service

  • Customer Center
  • Contact Us
  • WSJ Weekend
  • Contact Directory
  • Corrections
  • Policy

  • Privacy Policy
  • Cookie Policy
  • Data Policy
  • Copyright Policy
  • Updated :  Subscriber Agreement
    & Terms of Use
  • Your Ad Choices
  • Ads

  • Advertise
  • Place a Classified Ad
  • Sell Your Home
  • Sell Your Business
  • Commercial Real Estate Ads
  • Recruitment & Career Ads
  • Franchising
  • Advertise Locally
  • Tools & Features

  • Apps
  • Emails & Alerts
  • Graphics & Photos
  • Columns
  • Topics
  • Guides
  • Portfolio
  • Old Portfolio
  • More

  • Register for Free
  • Reprints
  • Content Partnerships
  • Conferences
  • Mobile Site
  • News Archive
  • Jobs at WSJ
  • Copyright ©2014 Dow Jones & Company, Inc. All Rights Reserved.